Crossmark

High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma

Crossref DOI link: https://doi.org/10.1007/s10822-021-00426-1

Published Online: 2021-11-02

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Al Shahrani, Mesfer

Abohassan, Mohammad

Y. Alshahrani, Mohammad

Hakami, Abdulrahim R.

Rajagopalan, Prasanna https://orcid.org/0000-0001-7593-7234
Funding

Funding for this research was provided by:

Deanship of Scientific Research at King Khalid University, Abha, Saudi Arabia (R.G.P.1/228/42)
License Information

Text and Data Mining valid from 2021-11-02

Version of Record valid from 2021-11-02
More Information

Article History

Received: 4 June 2021

Accepted: 20 October 2021

First Online: 2 November 2021

Declarations

:

: Authors declare that there is no any conflict of interest related to this study.

Document is current

Any future updates will be listed below